ALSO READSun Pharma Advanced Research Company reports standalone net loss of Rs 32.27 crore in the March 2017 quarter Sun Pharma Advanced Research Company to announce Q3 results USFDA subjects SPARC Xelpros nod to 'satisfactory resolution' SPARC gains after receiving USFDA's CRL for Xelpros SPARC Q3 net loss widens to Rs 66 crore
Announces top-line results of the PIF study and Low dose PK study for SPARC DPISun Pharma Advanced Research Company provided update on its breath activated device SPARC DPI.
SPARC DPI is a pre-metered, 60 dose, breath activated device containing Salmeterol - Fluticasone.
SPARC DPI uses half the dose of the both Salmeterol and Fluticasone compared to Seretide Accuhaler.
The Company announced the top-line results of the PIF study and Low dose PK study for SPARC DPI.
Anil Raghavan, CEO, SPARC said that the results confirms that the device is highly efficient and consistent in delivering more drug to the lungs and suitable for all classes of patients. The Company will consult the regulatory agencies in Europe to understand the potential path forward for SPARC DPI.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)